PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is trading at $0.42, about ₹40 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET, down 4.78% today. Indian residents can buy PharmaCyte Biotech from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$0.42
Today's high
$0.43
52 week low
$0.33
52 week high
$1.51
PMCB opened at $0.43, closed previously at $0.44, and has traded between $0.33 and $1.51 over the past 52 weeks.
About
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
Key statistics
Avg. volume
188.46K
Market cap
$4.51M
P/E Ratio
-0.17
Price-to-sales ratio
0.00
Enterprise value
-$13.23M
Free cash flow yield
-87.40%
Debt-to-equity ratio
0.00
Return on equity
-46.58%
ROIC
-19.51%
Beta
0.66
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$0.00
Earnings per share
-$2.77
Free cash flow
-$5.15M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-$5.30M
Revenue growth
—
Similar securities
This is not an investment recommendation
How to buy PharmaCyte Biotech from India
Indian residents can buy PharmaCyte Biotech shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for PharmaCyte Biotech and place an order
Find PharmaCyte Biotech by name or by its ticker, PMCB, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. PharmaCyte Biotech trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your PharmaCyte Biotech position in USD and INR. PharmaCyte Biotech pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in PharmaCyte Biotech from India
Trading and taxes when buying PharmaCyte Biotech from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NonePharmaCyte Biotech does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy PharmaCyte Biotech stock?
Yes. PharmaCyte Biotech (PMCB) has been listed on NASDAQ since 2013, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one PharmaCyte Biotech share cost in rupees?
One PharmaCyte Biotech share is $0.42 — about ₹40 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the PharmaCyte Biotech price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying PharmaCyte Biotech from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of PharmaCyte Biotech?
Yes. One PharmaCyte Biotech share is $0.42, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in PharmaCyte Biotech.
How are gains on PharmaCyte Biotech shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the PharmaCyte Biotech price. Paasa issues a capital-gains statement for your return.
Does PharmaCyte Biotech pay a dividend?
No. PharmaCyte Biotech does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade PharmaCyte Biotech from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on PharmaCyte Biotech shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare PharmaCyte Biotech shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your PharmaCyte Biotech holding, its cost and its closing value.
How do I sell PharmaCyte Biotech and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.